Published in Mol Cell Ther on December 13, 2013
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971
MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med (2016) 0.89
Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma. World J Hepatol (2015) 0.86
miR-124 interacts with the Notch1 signalling pathway and has therapeutic potential against gastric cancer. J Cell Mol Med (2015) 0.80
miR-155 Overexpression Promotes Genomic Instability by Reducing High-fidelity Polymerase Delta Expression and Activating Error-Prone DSB Repair. Mol Cancer Res (2016) 0.80
MicroRNA Expression in the Glaucomatous Retina. Invest Ophthalmol Vis Sci (2015) 0.80
The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells. Stem Cells Int (2016) 0.78
MicroRNAs and liver disease. J Hum Genet (2016) 0.77
MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression. J Clin Med (2015) 0.76
Technological advances in precision medicine and drug development. Expert Rev Precis Med Drug Dev (2016) 0.75
Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J Control Release (2016) 0.75
Inflammation-induced miRNA-155 inhibits self-renewal of neural stem cells via suppression of CCAAT/enhancer binding protein β (C/EBPβ) expression. Sci Rep (2017) 0.75
Identification of aminosulfonylarylisoxazole as microRNA-31 regulators. PLoS One (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
The functions of animal microRNAs. Nature (2004) 64.85
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 35.49
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 22.04
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
Nuclear export of microRNA precursors. Science (2003) 16.59
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
Processing of primary microRNAs by the Microprocessor complex. Nature (2004) 14.59
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods (2007) 13.94
Role of microRNAs in plant and animal development. Science (2003) 12.45
MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol (2005) 12.12
The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev (2004) 11.58
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A (2006) 10.11
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
MicroRNAs in Cancer. Annu Rev Med (2009) 9.37
Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell (2005) 9.27
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell (2011) 5.75
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res (2007) 5.67
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem (2007) 5.02
Epigenetic regulation by long noncoding RNAs. Science (2012) 4.74
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell (2009) 4.48
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science (2007) 4.33
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene (2008) 4.11
Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res (2004) 3.97
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
The long and short of microRNA. Cell (2013) 3.08
MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol (2009) 2.86
Emerging roles for natural microRNA sponges. Curr Biol (2010) 2.62
MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene (2010) 2.23
Functional complexity and regulation through RNA dynamics. Nature (2012) 2.07
Clinical applications for microRNAs in cancer. Clin Pharmacol Ther (2012) 2.05
MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res (2011) 1.97
MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology (2012) 1.96
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene (2011) 1.81
p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal (2011) 1.80
MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res (2011) 1.79
MicroRNAs in liver disease. Gastroenterology (2012) 1.76
Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods (2012) 1.67
The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis (2010) 1.65
MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun (2011) 1.41
MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology (2012) 1.39
MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK). Oncogene (2011) 1.36
MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology (2009) 1.34
MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett (2013) 1.24
Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol (2012) 1.23
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology (2012) 1.23
Combinatorial microRNAs: working together to make a difference. Cell Cycle (2008) 1.16
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res (2013) 1.14
Micro-RNAs in gastrointestinal and liver disease. Gastroenterology (2008) 1.09
microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). Int J Oncol (2011) 1.00
Applying small RNA molecules to the directed treatment of human diseases: realizing the potential. Expert Opin Ther Targets (2008) 0.94
Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials (2013) 0.93
Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo. Cell Biol Int (2012) 0.86
miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J Hepatol (2012) 0.82
MicroRNAs and liver function. Minerva Gastroenterol Dietol (2013) 0.78
Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. Drug Deliv (2012) 0.78